NASDAQ: MDCX · Life Sciences · 7 alerts · CIK 1997296
Share price
$1.69Close, Nov 16
Market cap
$3.25M
Shares outstanding
1.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Medicus Pharma Ltd. filings on SEC EDGAR ↗
Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.
Medicus Pharma Ltd. reported a net loss of $35.9 million for the nine months ended September 30, 2026, driven by $10 million in IPR&D charges and increased R&D spending. The company significantly strengthened its cash position through $17.2 million in ATM proceeds and $22 million from debentures, though it maintains a total shareholders' deficit of $10.5 million.
Medicus Pharma announced that its wholly-owned subsidiary, SkinJect, Inc., has entered into a non-binding letter of intent for a business combination with an undisclosed SPAC. The proposed transaction contemplates a $135 million pre-money enterprise valuation for SkinJect and is expected to close in the first half of 2027, with Medicus seeking to retain majority ownership.
Value
$135M
“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders. The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”
Medicus Pharma Ltd. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for ten consecutive business days. This compliance notice supersedes a delisting determination letter received on October 20, 2026, which had initially triggered a delisting process due to the company's failure to meet the bid price and stockholders' equity requirements.
Medicus Pharma Ltd. implemented a 1-for-50 reverse stock split (share consolidation) of its common shares effective October 12, 2026. The consolidation was previously approved by shareholders at the June 2026 annual meeting and is intended to adjust the company's share count and price on The Nasdaq Capital Market.
Medicus Pharma Ltd. announced a fifty-to-one (1-for-50) reverse stock split of its common shares effective October 12, 2026. The consolidation is intended to increase the per-share bid price to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The split was previously authorized by shareholders at the company's annual meeting on June 3, 2026.